Screener
Kyverna Therapeutics, Inc. KYTX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(39,728) | $(44,635) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Stock-based compensation | 3,171 | 2,161 |
| Accretion of discounts on available-for-sale marketable securities | (730) | (2,110) |
| Non-cash lease expense | 619 | 704 |
| Depreciation and amortization expense | 351 | 501 |
| Non-cash interest expense | 114 | — |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s stock-based comp?
- Kyverna Therapeutics, Inc. (KYTX) reported stock-based comp of $3.17M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Kyverna Therapeutics, Inc.'s stock-based comp increased by 46.7% year-over-year, from $2.16M to $3.17M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s stock-based comp?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s stock-based comp has grown at a 113.1% compound annual growth rate (CAGR), from $2.22M to $10.08M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Kyverna Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude